Answers are grounded in this paper and cite their sources.
Cohort study demonstrates low IgG levels post-nipocalimab treatment in infants, suggesting safety without adverse outcomes.
In this cohort of 12 live-born infants, antenatal treatment with nipocalimab resulted in low levels of detectable drug in fetal, neonatal, and infant samples. Treatment was associated with low IgG levels at birth; however, unusual or unexpected childhood illnesses or impaired vaccine responses were not observed. (Funded by Johnson & Johnson; ClinicalTrials.gov number, NCT03842189.).
No takes yet. Share an insight, caveat, or question.
Winter et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: